Adverse events30

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 30

Type	Event	Organ system	Group	Affected	At risk
other	Nasopharyngitis	Infections and infestations	Alogliptin 12.5 mg QD and Glimepiride QD or BID	20	105
other	Nasopharyngitis	Infections and infestations	Alogliptin 25 mg QD and Glimepiride QD or BID	20	104
other	Nasopharyngitis	Infections and infestations	Glimepiride 1, 2, 3 or 4 mg QD or BID	22	103
other	Headache	Nervous system disorders	Alogliptin 12.5 mg QD and Glimepiride QD or BID	0	105
other	Headache	Nervous system disorders	Alogliptin 25 mg QD and Glimepiride QD or BID	2	104
other	Headache	Nervous system disorders	Glimepiride 1, 2, 3 or 4 mg QD or BID	4	103
other	Fall	Injury, poisoning and procedural complications	Alogliptin 12.5 mg QD and Glimepiride QD or BID	1	105
other	Fall	Injury, poisoning and procedural complications	Alogliptin 25 mg QD and Glimepiride QD or BID	2	104
other	Fall	Injury, poisoning and procedural complications	Glimepiride 1, 2, 3 or 4 mg QD or BID	4	103
other	Gastroenteritis	Infections and infestations	Alogliptin 12.5 mg QD and Glimepiride QD or BID	4	105
other	Gastroenteritis	Infections and infestations	Alogliptin 25 mg QD and Glimepiride QD or BID	0	104
other	Gastroenteritis	Infections and infestations	Glimepiride 1, 2, 3 or 4 mg QD or BID	2	103
other	Upper respiratory tract inflammation	Respiratory, thoracic and mediastinal disorders	Alogliptin 12.5 mg QD and Glimepiride QD or BID	2	105
other	Upper respiratory tract inflammation	Respiratory, thoracic and mediastinal disorders	Alogliptin 25 mg QD and Glimepiride QD or BID	12	104
other	Upper respiratory tract inflammation	Respiratory, thoracic and mediastinal disorders	Glimepiride 1, 2, 3 or 4 mg QD or BID	3	103
other	Back pain	Musculoskeletal and connective tissue disorders	Alogliptin 12.5 mg QD and Glimepiride QD or BID	0	105
other	Back pain	Musculoskeletal and connective tissue disorders	Alogliptin 25 mg QD and Glimepiride QD or BID	4	104
other	Back pain	Musculoskeletal and connective tissue disorders	Glimepiride 1, 2, 3 or 4 mg QD or BID	1	103
serious	Cerebral infarction	Nervous system disorders	Alogliptin 12.5 mg QD and Glimepiride QD or BID	1	105
serious	Cerebral infarction	Nervous system disorders	Alogliptin 25 mg QD and Glimepiride QD or BID	0	104

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01318083/events

API reference For AI assistants

Adverse events30

Sources 3

Read this list from software.